Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
Level 5 - mechanism / opinion, no new human data
Narrative review and critical commentary without systematic review methodology
PubMed 38830549 · doi:10.1016/j.arr.2024.102348
What was done
This is a critical commentary and narrative review evaluating clinical trial claims and regulatory approvals for anti-amyloid monoclonal antibodies in Alzheimer's disease, specifically focusing on donanemab alongside aducanumab and lecanemab. The authors evaluate reported metrics of amyloid clearance, cognitive decline slowing, amyloid-related imaging abnormalities (ARIA), and brain volume changes.
What was found
The abstract cites reported trial claims for donanemab of up to an 86% reduction in cerebral amyloid and a 36% delay in cognitive decline relative to placebo. The authors state that on an absolute scale these changes are very small, arguably smaller than effects seen with cholinesterase inhibitors or memantine, and coincide with increased ARIA and accelerated brain volume loss. No primary statistical re-analyses or numerical absolute differences are quantified in the abstract.
Why it matters
It offers a critical appraisal of the risk-benefit ratio of anti-amyloid therapeutics, arguing that relative outcome metrics overstate clinical utility while downplaying potential harms.
Limits
This paper is a narrative commentary representing expert critique rather than a systematic review or new empirical clinical study. Specific absolute numerical values, trial sample sizes, and quantitative safety data are not detailed in the abstract.
Cited by
- supports In the donanemab trial, the treatment group showed measurable brain tissue loss (atrophy) compared to the placebo group.